

Key Inclusion Criteria
Statin-treated men and women ≥45 yrs
Established CVD (~70% of patients) or DM + ≥1 risk factor
TG ≥150 mg/dL and <500 mg/dL*
LDL-C >40 mg/dL and ≤100 mg/dL
Lead-in
Statin stabilization
Medication washout
Lipid qualification
1:1 Randomization with continuation of stable statin therapy (N=8179)
Icosapent Ethyl 4 g/day (n=4089)
Placebo (n=4090)
4 months, 12 months, annually
4 months, 12 months, annually
End-of-study follow-up visit
End-of-study follow-up visit
Primary Endpoint
Time for randomization to the first occurrence of composite of CV death, nonfatal MI, nonfatal stroke, coronary revascularization, unstable angina requiring hospitalization
Screening Period
Double-Blind Treatment/Follow-up Period
Randomization
End of Study
Year 0 Up to 6.2 years†
Months -1 Month 0 4 12 Every 12 months
Visit 1 2 3 4 5 6 7 8 9 Final Visit
Lab values Screening Baseline
* Due to the variability of triglycerides, a 10% allowance existed in the initial protocol, which permitted patients to be enrolled with qualifying triglycerides ≥135 mg/dL. Protocol amendment 1 (May 2013) changed the lower limit of acceptablel triglycerides from 150 mg/dL to 200 mg/dL, with no variability allowance.
† Median trial follow-up duration was 4.9 years (minimum 0.0, maximum 6.2 years).

FIG. 1



Screened
N=19,212
Screen Fails N=11,033*
Inc./Excl. criteria not met 10,429
Withdrawal of consent 340
Adverse event 13
Primary Prevention category closed 4
Death 5
Lost to follow-up 108
Enrollment closed 3
Other 135
*4 patients presented 2 screen failure reasons.
Randomized
N=8179
Icosapent Ethyl
N=4089 (100%)
Placebo
N=4090 (100%)
Completed Study N=3684 (90.1%)
Completed final visit 3419 (83.6%)
Death before final visit 265 (6.5%)
Completed Study N=3630 (88.8%)
Completed final visit 3335 (81.5%)
Death before final visit 295 (7.2%)
Early Discontinuation from Study N=405 (9.9%)*
Withdrawal of consent 281 (6.9%)
Investigator judgement 12 (0.3%)
Incomplete final visit 63 (1.5%)
Other 49 (1.2%)
Early Discontinuation from Study N=460 (11.2%)*
Withdrawal of consent 297 (7.3%)
Investigator judgement 12 (0.3%)
Incomplete final visit 89 (2.2%)
Other 62 (1.5%)
Actual vs. potential total follow-up time (%) 93.6%
Known vital status 4083 (99.9%)
Actual vs. potential total follow-up time (%) 92.9%
Known vital status 4077 (99.7%)

FIG. 2




A Primary End Point
Patients with an Event (%)
100
80
60
40
20
0
30
20
10
0
Hazard ratio, 0.75
(95% CI, 0.68-0.83)
P<0.001
Placebo
Icosapent Ethyl
0 1 2 3 4 5 6 7
0 1 2 3 4 5 6 7
Years since Randomization
No. at Risk
Placebo 4090 3743 3327 2807 2347 1358 7 0
AMR101 4089 3787 3431 2951 2503 1430 11 0

FIG. 3A



No. at Risk						
Placebo	**4090**	**3743**	**3327**	**2807**	**2347**	**1358**
VASCEPA	4089	3787	3431	2951	2503	1430

FIG. 3B



Endpoint
Hazard Ratio (95% CI)
Icosapent Ethyl n/N (%)
Placebo n/N (%)
Hazard Ratio (95% CI)*
Primary Composite (ITT)
705/4089 (17.2%)
901/4090 (22.0%)
0.75 (0.68-0.83)
Cardiovascular Death
174/4089 (4.3%)
213/4090 (5.2%)
0.80 (0.66-0.98)
Nonfatal Myocardial Infarction
237/4089 (5.8%)
332/4090 (8.1%)
0.70 (0.59-0.82)
Nonfatal Stroke
85/4089 (2.1%)
118/4090 (2.9%)
0.71 (0.54-0.94)
Coronary Revascularization
376/4089 (9.2%)
544/4090 (13.3%)
0.66 (0.58-0.76)
Hospitalization for Unstable Angina
108/4089 (2.6%)
157/4090 (3.8%)
0.68 (0.53-0.87)
0.4
1.0
1.4
Icosapent Ethyl Better
Placebo Better

FIG. 4




B Secondary End Point
Hazard ratio, 0.74
(95% CI, 0.65-0.83)
P<0.001
Placebo
Icosapent Ethyl
Patients with an Event (%)
Years since Randomization
No. at Risk
Placebo 4090 3837 3500 3002 2542 1487 8 0
Icosapent Ethyl 4089 3861 3565 3115 2681 1562 12 0

FIG. 5A



No. at Risk						
Placebo	**4090**	**3837**	**3500**	**3002**	**2542**	**1487**
VASCEPA	4089	3861	3565	3115	2681	1562

FIG. 5B



Endpoint
Hazard Ratio (95% CI)
Icosapent Ethyl n/N (%)
Placebo n/N (%)
HR(95% CI)*
Int pVal
Primary Composite 705/4089 (17.2%) 901/4090 (22.0%) 0.752 (0.682, 0.830)
Subgroup
Region 0.30
Western 551/2906 (19.0%) 713/2905 (24.5%) 0.740 (0.662, 0.827)
Eastern 143/1053 (13.6%) 167/1053 (15.9%) 0.842 (0.674, 1.053)
Asia Pacific 11/130 (8.5%) 21/132 (15.9%) 0.491 (0.236, 1.020)
Risk Category 0.64
Secondary Prevention 559/2892 (19.3%) 738/2893 (25.5%) 0.726 (0.650, 0.810)
Primary Prevention 146/1197 (12.2%) 163/1197 (13.6%) 0.876 (0.700, 1.095)
Ezetimibe Use 0.14
No 649/3827 (17.0%) 834/3828 (21.8%) 0.747 (0.675, 0.828)
Yes 56/262 (21.4%) 67/262 (25.6%) 0.816 (0.572, 1.164)
Sex 0.33
Male 551/2927 (18.8%) 715/2895 (24.7%) 0.732 (0.655, 0.818)
Female 154/1162 (13.3%) 186/1195 (15.6%) 0.818 (0.661, 1.013)
Age Group 0.004
<65 Years 322/2232 (14.4%) 460/2184 (21.1%) 0.650 (0.564, 0.750)
>=65 Years 383/1857 (20.6%) 441/1906 (23.1%) 0.873 (0.761, 1.001)
US vs. Non-US 0.14
USA 281/1548 (18.2%) 394/1598 (24.7%) 0.687 (0.590, 0.801)
Non-USA 424/2541 (16.7%) 507/2492 (20.3%) 0.803 (0.706, 0.913)
Baseline Diabetes 0.56
Diabetes 433/2394 (18.1%) 536/2393 (22.4%) 0.769 (0.687, 0.873)
No Diabetes 272/1695 (16.0%) 365/1694 (21.5%) 0.726 (0.620, 0.849)
TG>=200 mg/dL vs <200 mg/dL 0.45
TG>=200 mg/dL 430/2481 (17.3%) 559/2469 (22.6%) 0.730 (0.644, 0.828)
TG<200 mg/dL 275/1605 (17.1%) 342/1620 (21.1%) 0.791 (0.675, 0.927)
TG>=150 mg/dL vs <150 mg/dL 0.83
TG>=150 mg/dL 640/3674 (17.4%) 811/3660 (22.2%) 0.749 (0.675, 0.831)
TG<150 mg/dL 65/412 (15.8%) 90/429 (21.0%) 0.788 (0.571, 1.087)
TG>=200 and HDL-C<=35 0.04
Yes 149/823 (18.1%) 214/794 (27.0%) 0.623 (0.505, 0.769)
No 554/3258 (17.0%) 687/3293 (20.9%) 0.791 (0.707, 0.885)
Baseline Statin Intensity 0.12
High 232/1290(18.0%) 310/1226 (25.3%) 0.689 (0.581, 0.817)
Moderate 424/2533 (16.7%) 543/2575 (21.1%) 0.762 (0.671, 0.865)
Low 48/254 (18.9%) 45/267 (16.9%) 1.121 (0.743, 1.692)
hsCRP<=2 vs >2 mg/L 0.7
<=2 mg/L 288/1919 (15.0%) 407/1942 (21.0%) 0.680 (0.585, 0.791)
>2 mg/L 417/2167 (19.2%) 494/2147 (23.0%) 0.813 (0.713, 0.926)
hsCRP<=3 vs >3 mg/L 0.72
<=3 mg/L 402/2497 (16.1%) 535/2547 (21.0%) 0.739 (0.649, 0.841)
>3 mg/L 303/1589 (19.1%) 366/1542 (23.7%) 0.762 (0.655, 0.888)
0.2
0.6
1.0
1.4
1.8
Icosapent Ethyl Better
Placebo Better

FIG. 6



End Point/Subgroup
Hazard Ratio (95% CI)
Icosapent Ethyl n/N (%)
Placebo n/N (%)
HR(95% CI)*
Int P Val
Primary Composite Endpoint (ITT) 705/4089 (17.2%) 901/4090 (22.0%) 0.75 (0.68-0.83)
Subgroup
Risk Category 0.14
Secondary Prevention Cohort 559/2892 (19.3%) 738/2893 (25.5%) 0.73 (0.65-0.81)
Primary Prevention Cohort 146/1197 (12.2%) 163/1197 (13.6%) 0.88 (0.70-1.10)
Region 0.30
Western 551/2906 (19.0%) 713/2905 (24.5%) 0.74 (0.66-0.83)
Eastern 143/1053 (13.6%) 167/1053 (15.9%) 0.84 (0.67-1.05)
Asia Pacific 11/130 (8.5%) 21/132 (15.9%) 0.49 (0.24-1.02)
Ezetimibe Use 0.64
No 649/3827 (17.0%) 834/3828 (21.8%) 0.75 (0.67-0.83)
Yes 56/262 (21.4%) 67/262 (25.6%) 0.82 (0.57-1.16)
Sex 0.33
Male 551/2927 (18.8%) 715/2895 (24.7%) 0.73 (0.65-0.82)
Female 154/1162 (13.3%) 186/1195 (15.6%) 0.82 (0.66-1.01)
White vs Non-White 0.18
White 646/3691 (17.5%) 812/3688 (22.0%) 0.77 (0.69-0.85)
Non-White 59/398 (14.8%) 89/401 (22.2%) 0.60 (0.43-0.83)
Age Group 0.004
<65 Years 322/2232 (14.4%) 460/2184 (21.1%) 0.65 (0.56-0.75)
>=65 Years 383/1857 (20.6%) 441/1906 (23.1%) 0.87 (0.76-1.00)
US vs. Non-US 0.14
USA 281/1548 (18.2%) 394/1598 (24.7%) 0.69 (0.59-0.80)
Non-USA 424/2541 (16.7%) 507/2492 (20.3%) 0.80 (0.71-0.91)
Baseline Diabetes 0.56
Diabetes 433/2394 (18.1%) 536/2393 (22.4%) 0.77 (0.68-0.87)
No Diabetes 272/1695 (16.0%) 365/1694 (21.5%) 0.73 (0.62-0.85)
Baseline eGFR 0.41
<60 mL/min/1.73m2 197/905 (21.8%) 263/911 (28.9%) 0.71 (0.59-0.85)
60-<90mL/min/1.73m2 380/2217 (17.1%) 468/2238 (20.9%) 0.80 (0.70-0.92)
≥90 mL/min/1.73m2 128/963 (13.3%) 170/939 (18.1%) 0.70 (0.56-0.89)
Baseline TG≥200 vs <200 mg/dL 0.45
TG≥200 mg/dL 430/2481 (17.3%) 559/2469 (22.6%) 0.73 (0.64-0.83)
TG<200 mg/dL 275/1605 (17.1%) 342/1620 (21.1%) 0.79 (0.67-0.93)
Baseline TG≥150 vs <150 mg/dL 0.83
TG≥150 mg/dL 640/3674 (17.4%) 811/3660 (22.2%) 0.75 (0.68-0.83)
TG<150 mg/dL 65/412 (15.8%) 90/429 (21.0%) 0.79 (0.57-1.09)
Baseline TG≥200 and HDL-C≤35 mg/dL 0.04
Yes 149/823 (18.1%) 214/794 (27.0%) 0.62 (0.51-0.77)
No 554/3258 (17.0%) 687/3293 (20.9%) 0.79 (0.71-0.88)
Baseline Statin Intensity 0.12
High 232/1290(18.0%) 310/1226 (25.3%) 0.69 (0.58-0.82)
Moderate 424/2533 (16.7%) 543/2575 (21.1%) 0.76 (0.67-0.86)
Low 48/254 (18.9%) 45/267 (16.9%) 1.12 (0.74-1.69)
Baseline LDL-C (Derived) by Tertiles 0.62
≤67 mg/dL 244/1481 (16.5%) 302/1386 (21.8%) 0.72 (0.61-0.85)
>67-≤84 mg/dL 248/1347 (18.4%) 307/1364 (22.5%) 0.81 (0.68-0.96)
>84 mg/dL 213/1258 (16.9%) 292/1339 (21.8%) 0.74 (0.62-0.89)
Baseline hsCRP≤2 vs >2 mg/L 0.7
≤2 mg/L 288/1919 (15.0%) 407/1942 (21.0%) 0.68 (0.58-0.79)
>2 mg/L 417/2167 (19.2%) 494/2147 (23.0%) 0.81 (0.71-0.93)
0.2
0.6
1.0
1.4
1.8
Icosapent Ethyl Better
Placebo Better

FIG. 7



End Point
Hazard Ratio (95% CI)
Icosapent Ethyl n/N (%)
Placebo n/N (%)
HR(95% CI)*
Int P Val
Key Secondary Composite (ITT) 459/4089 (11.2%) 606/4090 (14.8%) 0.74 (0.65-0.83)
Subgroup
Risk Category 0.46
Secondary Prevention 361/2892 (12.5%) 489/2893 (16.9%) 0.72 (0.63-0.82)
Primary Prevention 98/1197 (8.2%) 117/1197 (9.8%) 0.81 (0.62-1.06)
Region 0.54
Western 358/2906 (12.3%) 473/2905 (16.3%) 0.73 (0.64-0.84)
Eastern 93/1053 (8.8%) 117/1053 (11.1%) 0.78 (0.59-1.02)
Asia Pacific 8/130 (6.2%) 16/132 (12.1%) 0.47 (0.20-1.10)
Ezetimibe Use 0.41
No 426/3827 (11.1%) 569/3828 (14.9%) 0.73 (0.64-0.82)
Yes 33/262 (12.6%) 37/262 (14.1%) 0.87 (0.55-1.39)
Sex 0.44
Male 353/2927 (12.1%) 474/2895 (16.4%) 0.72 (0.62-0.82)
Female 106/1162 (9.1%) 132/1195 (11.0%) 0.80 (0.62-1.03)
Age Group 0.06
<65 Years 200/2232 (9.0%) 290/2184 (13.3%) 0.65 (0.54-0.78)
>=65 Years 259/1857 (13.9%) 316/1906 (16.6%) 0.82 (0.70-0.97)
US vs. Non-US 0.38
USA 187/1548 (12.1%) 266/1598 (16.6%) 0.69 (0.57-0.83)
Non-USA 272/2541 (10.7%) 340/2492 (13.6%) 0.77 (0.66-0.91)
Baseline Diabetes 0.29
Diabetes 286/2394 (11.9%) 391/2393 (16.3%) 0.70 (0.60-0.81)
No Diabetes 173/1695 (10.2%) 215/1694 (12.7%) 0.80 (0.65-0.98)
Baseline TG≥200 vs <200 mg/dL 0.62
TG≥200 mg/dL 290/2481 (11.7%) 371/2469 (15.0%) 0.75 (0.65-0.88)
TG<200 mg/dL 169/1605 (10.5%) 235/1620 (14.5%) 0.71 (0.58-0.86)
Baseline TG≥150 vs <150 mg/dL 0.68
TG≥150 mg/dL 421/3674 (11.5%) 546/3660 (14.9%) 0.74 (0.65-0.84)
TG<150 mg/dL 38/412 (9.2%) 60/429 (14.0%) 0.66 (0.44-0.99)
Baseline TG≥200 and HDL-C≤35 mg/dL 0.50
Yes 101/823 (12.3%) 136/794 (17.1%) 0.68 (0.53-0.88)
No 356/3258 (10.9%) 470/3293 (14.3%) 0.75 (0.65-0.86)
Baseline Statin Intensity 0.10
High 151/1290(11.7%) 210/1226 (17.1%) 0.66 (0.54-0.82)
Moderate 270/2533 (10.7%) 361/2575 (14.0%) 0.74 (0.63-0.87)
Low 37/254 (14.6%) 32/267 (12.0%) 1.20 (0.74-1.94)
Baseline hsCRP≤2 vs >2 mg/L 0.97
≤2 mg/L 183/1919 (9.5%) 245/1942 (12.6%) 0.73 (0.61-0.89)
>2 mg/L 276/2167 (12.7%) 361/2147 (16.8%) 0.73 (0.63-0.86)
Baseline hsCRP≤3 vs >3 mg/L 0.95
≤3 mg/L 250/2497 (10.0%) 341/2547 (13.4%) 0.73 (0.62-0.86)
>3 mg/L 209/1589 (13.2%) 265/1542 (17.2%) 0.74 (0.61-0.88)
0.2
0.6
1.0
1.4
1.8
Icosapent Ethyl Better
Placebo Better

FIG. 8



End Point/Subgroup
Hazard Ratio (95% CI)
Icosapent Ethyl n/N (%)
Placebo n/N (%)
HR(95% CI)*
Int P Val
Key Secondary Composite Endpoint (ITT) 459/4089 (11.2%) 606/4090 (14.8%) 0.74 (0.65-0.83)
Subgroup
Risk Category 0.41
Secondary Prevention Cohort 361/2892 (12.5%) 489/2893 (16.9%) 0.72 (0.63-0.82)
Primary Prevention Cohort 98/1197 (8.2%) 117/1197 (9.8%) 0.81 (0.62-1.06)
Region 0.54
Western 358/2906 (12.3%) 473/2905 (16.3%) 0.73 (0.64-0.84)
Eastern 93/1053 (8.8%) 117/1053 (11.1%) 0.78 (0.59-1.02)
Asia Pacific 8/130 (6.2%) 16/132 (12.1%) 0.47 (0.20-1.10)
Ezetimibe Use 0.46
No 426/3827 (11.1%) 569/3828 (14.9%) 0.73 (0.64-0.82)
Yes 33/262 (12.6%) 37/262 (14.1%) 0.87 (0.55-1.39)
Sex 0.44
Male 353/2927 (12.1%) 474/2895 (16.4%) 0.72 (0.62-0.82)
Female 106/1162 (9.1%) 132/1195 (11.0%) 0.80 (0.62-1.03)
White vs Non-White 0.13
White 418/3691 (11.3%) 538/3688 (14.6%) 0.76 (0.67-0.86)
Non-White 41/398 (10.3%) 68/401 (17.0%) 0.55 (0.38-0.82)
Age Group 0.06
<65 Years 200/2232 (9.0%) 290/2184 (13.3%) 0.65 (0.54-0.78)
≥65 Years 259/1857 (13.9%) 316/1906 (16.6%) 0.82 (0.70-0.97)
US vs. Non-US 0.38
USA 187/1548 (12.1%) 266/1598 (16.6%) 0.69 (0.57-0.83)
Non-USA 272/2541 (10.7%) 340/2492 (13.6%) 0.77 (0.66-0.91)
Baseline Diabetes 0.29
Diabetes 286/2394 (11.9%) 391/2393 (16.3%) 0.70 (0.60-0.81)
No Diabetes 173/1695 (10.2%) 215/1694 (12.7%) 0.80 (0.65-0.98)
Baseline eGFR 0.77
<60 mL/min/1.73m2 152/905 (16.8%) 205/911 (22.5%) 0.71 (0.57-0.88)
60-<90mL/min/1.73m2 229/2217 (10.3%) 296/2238 (13.2%) 0.77 (0.64-0.91)
≥90 mL/min/1.73m2 78/963 (8.1%) 105/939 (11.2%) 0.70 (0.52-0.94)
Baseline TG≥200 vs <200 mg/dL 0.62
TG≥200 mg/dL 290/2481 (11.7%) 371/2469 (15.0%) 0.75 (0.65-0.88)
TG<200 mg/dL 169/1605 (10.5%) 235/1620 (14.5%) 0.71 (0.58-0.86)
Baseline TG≥150 vs <150 mg/dL 0.68
TG≥150 mg/dL 421/3674 (11.5%) 546/3660 (14.9%) 0.74 (0.65-0.84)
TG<150 mg/dL 38/412 (9.2%) 60/429 (14.0%) 0.66 (0.44-0.99)
Baseline TG≥200 and HDL-C≤35 mg/dL 0.50
Yes 101/823 (12.3%) 136/794 (17.1%) 0.68 (0.53-0.88)
No 356/3258 (10.9%) 470/3293 (14.3%) 0.75 (0.65-0.86)
Baseline Statin Intensity 0.10
High 151/1290(11.7%) 210/1226 (17.1%) 0.66 (0.54-0.82)
Moderate 270/2533 (10.7%) 361/2575 (14.0%) 0.74 (0.63-0.87)
Low 37/254 (14.6%) 32/267 (12.0%) 1.20 (0.74-1.94)
Baseline LDL-C (Derived) by Tertiles 0.97
≤67 mg/dL 157/1481 (10.6%) 196/1386 (14.1%) 0.73 (0.59-0.90)
>67-≤84 mg/dL 157/1347 (11.7%) 208/1364 (15.2%) 0.75 (0.61-0.93)
>84 mg/dL 145/1258 (11.5%) 202/1339 (15.1%) 0.74 (0.60-0.91)
Baseline hsCRP≤2 vs >2 mg/L 0.97
≤2 mg/L 183/1919 (9.5%) 245/1942 (12.6%) 0.73 (0.61-0.89)
>2 mg/L 276/2167 (12.7%) 361/2147 (16.8%) 0.73 (0.63-0.86)
0.2
0.6
1.0
1.4
1.8
Icosapent Ethyl Better
Placebo Better

FIG. 9



A Primary End Point by Achieved Triglyceride Level at 1 Year
Hazard ratio (95% CI):
Icosapent Ethyl Triglyceride <150 vs ≥150 mg/dL 0.99 (0.84-1.16)
Icosapent Ethyl Triglyceride ≥150 mg/dL vs Placebo 0.71 (0.63-0.79)
Icosapent Ethyl Triglyceride <150 mg/dL vs Placebo 0.70 (0.60-0.81)
Placebo
Icosapent Ethyl Triglyceride ≥150 mg/dL
Icosapent Ethyl Triglyceride <150 mg/dL
Patients with an Event (%)
100
90
80
70
60
50
40
30
20
10
0
0
1
2
3
4
5
Years since Randomization
No. at Risk
Placebo 4090 3743 3327 2807 2347 1358
Icosapent Ethyl Triglyceride ≥150 mg/dL 2364 2276 2085 1775 1473 803
Icosapent Ethyl Triglyceride <150 mg/dL 1325 1277 1179 1040 922 571
B Key Secondary End Point by Achieved Triglyceride Level at 1 Year
Hazard ratio (95% CI):
Icosapent Ethyl Triglyceride <150 vs ≥150 mg/dL 1.00 (0.82-1.23)
Icosapent Ethyl Triglyceride ≥150 mg/dL vs Placebo 0.67 (0.56-0.80)
Icosapent Ethyl Triglyceride <150 mg/dL vs Placebo 0.66 (0.57-0.77)
Placebo
Icosapent Ethyl Triglyceride ≥150 mg/dL
Icosapent Ethyl Triglyceride <150 mg/dL
Patients with an Event (%)
100
90
80
70
60
50
40
30
20
10
0
0
1
2
3
4
5
Years since Randomization
No. at Risk
Placebo 4090 3837 3500 3002 2542 1487
Icosapent Ethyl Triglyceride ≥150 mg/dL 2364 2319 2171 1875 1579 879
Icosapent Ethyl Triglyceride <150 mg/dL 1325 1300 1218 1096 986 620

FIG. 10




Endpoint
Hazard Ratio (95% CI)
Icosapent Ethyl n/N (%)
Placebo n/N (%)
HR (95% CI)
p-Value
Primary Composite (ITT) 705/4089 (17.2%) 901/4090 (22.0%) 0.752 (0.682, 0.830) <.0001
Key Secondary Composite (ITT) 459/4089 (11.2%) 606/4090 (14.8%) 0.735 (0.651, 0.830) <.0001
CV Death or Non-Fatal MI 392/4089 (9.6%) 507/4090 (12.4%) 0.753 (0.660, 0.859) <.0001
Fatal or Non-Fatal MI 250/4089 (6.1%) 355/4090 (8.7%) 0.688 (0.585, 0.808) <.0001
Urgent or Emergent Revasc 216/4089 (5.3%) 321/4090 (7.8%) 0.653 (0.550, 0.776) <.0001
CV Death 174/4089 (4.3%) 213/4090 (5.2%) 0.803 (0.657, 0.981) 0.03
Hosp. for UA 108/4089 (2.6%) 157/4090 (3.8%) 0.679 (0.531, 0.868) 0.002
Fatal or Non-Fatal Stroke 98/4089 (2.4%) 134/4090 (3.3%) 0.720 (0.555, 0.934) 0.01
Total Mortality/Non-Fatal MI/Non-Fatal Stroke 549/4089 (13.4%) 690/4090 (16.9%) 0.772 (0.690, 0.864) <.0001
Total Mortality 274/4089 (6.7%) 310/4090 (7.6%) 0.870 (0.739, 1.023) ns
0.2
0.6
1.0
1.4
1.8
Icosapent Ethyl Better
Placebo Better

FIG. 11



*Elevated-TG cohort: TG ≥1.69 mmol/L (≥150 mg/dL).

†Comparator cohort: TG <1.69 mmol/L (<150 mg/dL) and HDL-C >1.04 mmol/L (>40 mg/dL).

‡Population used for multivariate analyses.

§Population used for patient characteristics and other analyses.

FIG. 12